Cardiff Oncology, Inc.
CRDF· Nasdaq
CRDFCardiff Oncology, Inc.
Filed Mar 6, 2019 · 10-K · 65 days after period end · 0001628280-19-002546
derived · Computed from the longer spans the company filed.
| Metric | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | $78.02K | $185.00K | $68.00K | $79.00K |
| Net Income | -$4.16M | -$2.57M | -$8.55M | -$7.38M |
| EPS Diluted | — | -$0.06 | -$0.34 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
ended Dec 31, 2018 · filed Mar 6, 2019 · 65 d after period end
